Dr. Matt Thompson is the President and Chief Executive Officer (CEO) of Endologix LLC. Prior to his CEO appointment in November 2021, he served as the company’s Chief Medical Officer (CMO) from 2016, overseeing business development, medical affairs, regulatory, clinical, and R&D departments. Among his notable contributions as CMO was to lead the  acquisition and integration of PQ Bypass in April 2021.

Previously he was the Professor of Vascular Surgery at St George’s, University of London and Staff Surgeon in the Department of Vascular Surgery at the Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Ohio. Dr. Thompson trained at Cambridge, St Bartholomew’s Hospital, the University of Leicester and Adelaide. He studied corporate innovation at Stanford University, Graduate School of Business. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. His named lectures include the Kinmonth Lecture (Vascular Society Great Britain and Ireland), the British Journal of Surgery Lecture (Vascular Society Great Britain and Ireland), and the Chee Song Memorial Lecture (British Society of Endovascular Therapy). He has published over 400 peer reviewed articles.

His clinical interests were in the treatment of aortic disease and endovascular surgery. His research interests include health service outcome research, clinical trials, and translational investigations into aortic disease. Dr. Thompson is the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He has been the clinical director for three London-wide service reconfigurations (cardiovascular disease, major trauma, and emergency services). He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services. He is a founder of the British Society for Endovascular Therapy, a past Council Member of the Vascular Society, was Chairman of the Vascular Society Annual Scientific Meeting and was awarded a Lifetime Achievement Award by the Vascular Society of Great Britain and Ireland in 2017.

Cindy Pinto was appointed as the Chief Financial Officer in March 2021 after serving as the Interim CFO and principal financial officer since June 2020. During her tenure, she has held various positions in the Finance Department, most recently she was the Vice President, Financial Planning and Analysis. Prior to that, Cindy served as the Company’s Senior Finance Director from February 2016 through September 2018 and as Finance Director from September 2014 through January 2016. Prior to joining Endologix, Cindy served as Finance Director at Covidien. She received a BS in Accounting from Villanova University and an MBA from New York University. During her free time Cindy enjoys hiking, traveling and spending time with her family.

Mike joined Endologix as the Chief Commercial Officer in March 2024. Mike Mathias has spent his thirty-year career successfully leading commercial organizations in the cardiovascular space. Most recently, he played a seminal role as Vice President, Commercial Operations at LimFlow, Inc. which Inari Medical acquired. As the LimFlow, Inc., commercial leader, he led the development and execution of the LimFlow System’s U.S. commercial launch. Prior to joining LimFlow, Inc., he spent 20 years in various commercial leadership roles at Medtronic. He led Medtronic’s $1.2 billion Heart Valve Therapies U.S commercial operations, launching TAVR (Transcatheter Aortic Valve Replacement). Prior to leading the Heart Valve Therapies commercial organization, he held sales management roles across Medtronic’s cardiology, endovascular, cardiac surgery, peripheral, perfusion, and cardiac rhythm businesses, as well as a variety of sales roles in the cardiology franchise for Pfizer. He earned a B.S. in Arabic and French Studies at the U.S. Military Academy at West Point and holds a master’s degree in business administration from the University of Minnesota.

Graham Phillips joined Endologix as Chief Operating Officer in June 2024, In his role, Graham oversees manufacturing, supply chain, R&D, regulatory affairs, and quality, playing a critical role in shaping the company’s operational strategy and enhancing its production capabilities to meet global demands.

Prior to joining Endologix, Graham served as Vice President of Manufacturing for the Americas East Region at Medtronic, where he managed a large global team across 25 manufacturing sites from Canada to Brazil, including the Caribbean, the Mid-West, and the U.S. East Coast. His responsibilities at Medtronic included oversight of safety, quality, delivery and cost supporting more than 50% of revenue.

Graham also managed significant organizational changes such as the Operations element of the Mallinckrodt Pharmaceuticals spin-off and the Covidien Operations segment of the integration with Medtronic. His international experience includes roles in Europe managing acquisitions, divestitures, and a reduction in manufacturing footprint, alongside project managing for Covidien the setting up of R&D in China, India and Singapore plus the realignment of the company’s tax management to its strategy and legal structure.

Prior to his extensive career in Medical Devices, Graham held key manufacturing management positions at Budelpack (a third party European contract manufacturer) and roles of increasing responsible in Operations at Kraft Foods.

Graham holds an undergraduate bachelor’s degree in Mechanical Engineering from the University of Teesside, UK; an MBA from the University of Warwick Business School, UK and an Advanced Management qualification from Chicago Booth Business School.  He is a Chartered Engineer with the UK Institute of Mechanical Engineers and holds a Six Sigma Black Belt.  Graham also previously taught short courses in Entrepreneurial Innovation at Shanghai Jiao Tong University. 

Matt has over 25 years of experience within the medical device industry, having roles within the R&D and Operations functions of global corporations and emerging technical companies. Prior to being appointed as the VP, Engineering at Endologix, he held various leadership positions within the Engineering department, most recently as the Senior Director of Manufacturing Engineering. Previous to Endologix, Matt held leadership positions of increasing responsibility over his 25 year career with Medtronic CardioVascular in Danvers, MA and with the Medtronic Coronary/Renal Denervation/Structural Heart divisions in Santa Rosa, CA. Matt’s diverse and extensive experience comes from executing as a functional, technical, and program leader across numerous internal and external development programs, along with cross business partnerships within the Peripheral and Cardiac Rhythm Management space.

Matt holds a BS in Industrial Engineering and an AS in Plastic Engineering Technology from the University of Massachusetts-Lowell and has attended MIT Sloan School of Management for Executive MBA studies. During his spare time, he enjoys ice hockey, golf, winemaking, and spending time with his family.

Chip Richter joined Endologix as Vice President of Health Economics & Reimbursement in January 2023. He is a healthcare executive and leader with over two decades of experience in healthcare economics, reimbursement, health policy and government affairs.

Chip has a passion for translating national policy trends into practical go-to-market strategies and successfully achieving company reimbursement goals. He joins Endologix from Artio, where he established healthcare economics and reimbursement programs in preparation for the company’s product launches in the peripheral vascular and the end-stage kidney disease spaces.  Prior to that, Chip was instrumental in helping iCAD to navigate a new Medicare payment model for radiation oncology. Chip has held roles of increasing healthcare economics and reimbursement responsibility with PROCEPT BioRobotics, St Jude Medical, and Abbott Vascular.

Chip holds a BA in Sociology and Philosophy from Cabrini College and a Master of Public Health (MPH) from Johns Hopkins University.

Kathryn Simpson joined Endologix as the VP of Regulatory Affairs in September 2024. Prior to joining Endologix, Kathryn served as Vice President of Regulatory Affairs at Edwards Lifesciences, where she oversaw regulatory efforts across multiple novel transcatheter mitral and tricuspid valve therapies in various stages of development. Before her time at Edwards, she worked at Medtronic in the Spine and Biologics business. There, she led regulatory activities for the spinal portfolio and played a key role in the development and commercialization of a number of first-of-a-kind devices and procedural innovations. Kathryn holds a PhD in Bioengineering from Rice University and a BS in Electrical Engineering from the University of Memphis. With 20 years of experience in the regulatory field, Kathryn will significantly contribute to the development of Endologix.

William has over 20 years of experience within the medical device industry, having roles within Quality, Regulatory, R&D, and Operations with both start-ups and large corporations. He has extensive experience in transformational leadership, and Quality Management System and product development. Prior to joining, William was Vice President of Quality and Regulatory at Triad Life Sciences where he assisted the company with commercialization of their advanced wound management products. He has held various roles throughout his career with companies such as Becton Dickinson and Medtronic, and previously owned a medical device consulting company specializing in quality, operational management, and regulatory affairs. He has a degree in Mechanical Engineering from the University of Memphis. During his free time, he enjoys spending time with his family, fishing, and restoring classic cars.